

Interaction Report

Report ID:
Date Produced: 23 May 2025

Antiretroviral Treatment**Co-medications**

Emtricitabine (FTC)
Lamivudine (3TC)
Tenofovir-DF (TDF)

Gentamicin

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org.

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Tenofovir-DF (TDF) + Gentamicin

Coadministration has not been studied. As gentamicin is eliminated unchanged predominantly via renal glomerular filtration, there is little potential for interaction with tenofovir-DF via competition for active renal transport mechanisms. However, both gentamicin and tenofovir-DF are potentially nephrotoxic and tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic agent. If concomitant use of tenofovir-DF and nephrotoxic agents is unavoidable, renal function should be monitored closely.

No clinically significant interaction expected (GREEN)

Emtricitabine (FTC) + Gentamicin**Lamivudine (3TC) + Gentamicin**